 |
|
|
|
|
|
|
 |
|
| PROPOSED METHOD |
|
 |
 |
 |
 |
|
 Damaged heart muscle due to heart attack.
|
 Clinical diagnosis of myocardial ischemia and myocardial infarction. |
 Biohearts non-surgical catheter-based proprietary myocardial tissue regeneration approach. |
|
|
 |
|
 |
 |
 |
|
 Administration of cellular implants through needle catheter by an interventional cardiologist or cardiovascular surgeon. |
 & |
 Closeups of pellet insertion into damaged heart muscle tissue. |
|
|
 |
|
 |
 |
 |
|
 Pellets integrating into heart muscle tissue. |
 Growth of new heart muscle cells and blood vessels (new blood vessel formation may be facilitated or enhanced with separate injections or channels made by utilizing technologies of other companies specializing in angiogenesis), partially reviving damaged heart region. |
 Intended outcome - improved heart function and reduction of angina following myocardial regeneration procedure. |
|
|
BACK TO
BIOHEART, INC. INDEX
|
|
| This new and innovative medical treatment will be the subject of a planned upcoming Phase 1/2 clinical trial which is yet to be initiated. The Company has not yet completed development or received FDA approval for its potential myocardial cellular implant products. Permission to begin human studies has not been granted by the FDA, as of February 2000. |
|
| © Bioheart, Inc., Weston, Florida USA |
|